BIOVIE INC. Segments Disclosure
On July 4, 2025, the U.S. enacted the One Big Beautiful Bill Act (the “Act”), which contains a broad range of tax reform provisions affecting businesses. The Company is currently evaluating the full effects of the Act and does not anticipate a material impact on the financial statements.
| 13. | Segment Reporting |
The Company operates as one operating segment with a focus on its efforts to develop drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. The Company's CEO, as the chief operating decision maker, manages and allocates resources to the operations of the Company based on the line items included within these financial statements and segment performance is evaluated based on net loss. This enables the CEO to assess the overall level of available resources and determine how best to deploy these resources across functions, clinical trials, and development projects in line with the long-term company-wide strategic goals. The measurement of segment assets is reported on the balance sheet as total assets. All of the Company’s tangible assets are held in the United States.
The following table presents selected financial information with respect to the Company’s single operating segment and its significant segment expenses for the years ended June 30, 2025 and 2024:
| For the Year Ended | For the Year Ended | |||||||
| June 30, 2025 | June 30, 2024 | |||||||
| Clinical studies | $ | 3,660,000 | $ | 11,081,000 | ||||
| Clinical teams | 4,479,000 | 8,873,000 | ||||||
| Chemistry, manufacturing and controls | 834,000 | 2,066,000 | ||||||
| Other research and development expenses | 294,000 | 1,081,000 | ||||||
| Selling, general and administrative expenses | 8,570,000 | 8,850,000 | ||||||
Amortization of intangible assets | 229,000 | 229,000 | ||||||
Other income, net | (524,000 | ) | (59,000 | ) | ||||
Net loss | $ | (17,542,000 | ) | $ | (32,121,000 | ) | ||
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.